转化生长因子β1及基质金属蛋白酶抑制剂1、2siRNA真核表达载体的构建与鉴定

Construction and identification of siRNA eukaryotic expression vectors targeting on TGF β1, TIMP-1 and TIMP-2 genesin vitro

目的 用RNA干扰技术,分别以转化生长因子（TGF）β 1、基质金属蛋白酶抑制剂（TIMP）-1和TIMP-2为靶基因,设计并构建针对TGF β 1、TIMP-1和TIMP-2基因的小干扰RNA（siRNA）真核表达载体,并在体外检测其对大鼠肝星状细胞株（HSC-T6）的TGF β 1、TIMP-1和TIMP-2基因表达的抑制情况.方法 设计合成TGF β 1、TIMP-1和TIMP-2的siRNA并与含绿色荧光蛋白的pGenesil-1载体连接,构建siRNA真核表达载体,并测序鉴定.体外转染HSC-T6细胞,观察转染效率,并用荧光定量PCR以及Western blot分析对目的 基因的抑制效率.组间比较用方差分析,两两比较用q检验.结果 成功构建了针对TGF β 1、TIMP-1和TIMP-2基因的siRNA真核表达载体.体外成功转染HSC-T6细胞,转染后的细胞TGF β 1、TIMP-1及TIMP-2 mRNA表达分别下调63.4%±8.0%,64.5%±9.0%,55.0%±17.0%（F值分别为17.55、128.42、210.36,P值均＜0.01）,TGF β 1、TIMP-1及TIMP-2蛋白表达分别下降57.8%±3.0%,55.1%±5.0%,49.3%±1.0%（F值分别为130.75、159.09、35.72,P值均＜0.01）.结论 成功构建了针对TGF β 1、TIMP-1和TIMP-2基因的siRNA真核表达载体;将重组载体成功转染入体外培养的HSC-T6细胞,并显著抑制了目的 基因的表达;为进一步研究其在体抑制表达提供了实验工具.

Objective To construct the siRNA eukaryotic expression vectors targeting on TGF β1,TIMP-1 and TIMP-2 and to investigate the inhibitory efficiency of target genes expression on rat hepatic stellate cell in vitro. Methods The siRNA cDNA sequences ofTGF β 1, TIMP-1 and TIMP-2 were designed,synthesized and inserted into plasmid pGenesil-1 respectively to generate eukaryotic expression plasmids.The plasmids were transfected into HSC T6 cells in vitro and the inhibitory efficiency of target genes expression was observed with real-time PCR and Western blot. Results The eukaryotic expression vectors were constructed successfully. The expressions of TGF β1 mRNA, TIMP-1 mRNA and TIMP-2mRNA in siRNAtransfected groups were decreased by 63.4% ± 8.0%, 64.5% ± 9.0% and 55.0% ± 17.0% respectively and the expressions of TGF β1 protein, TIMP-1 protein and TIMP-2 protein were decreased by 57.8% ± 3.0%,55.1% ± 5.0%, 49.3% ± 1.0% respectively as compared to the control groups. Conclusions The siRNA eukaryotic expression vectors constructed targeting on TGF β1, TIMP-1 and TIMP-2 could reduce the expressions of target genes and they might be able to used for the exploration of new anti-fibrosis drugs genetically.